CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
December 09, 2024 12:00 ET
|
CRISPR Therapeutics AG
-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced...
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
November 14, 2024 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
November 07, 2024 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 05, 2024 09:01 ET
|
CRISPR Therapeutics AG
-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 05, 2024 16:01 ET
|
CRISPR Therapeutics AG
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials...
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
May 29, 2024 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
May 23, 2024 08:00 ET
|
CRISPR Therapeutics AG
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) --...
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
May 09, 2024 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 08, 2024 16:00 ET
|
CRISPR Therapeutics AG
-More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected- -Clinical trials ongoing for next generation CAR T product...
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
May 08, 2024 07:00 ET
|
CRISPR Therapeutics AG
- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands...